Home spirometry in patients with idiopathic pulmonary fibrosis: Data from the INMARK trial

Imre Noth; Vincent Cottin; Nazia Chaudhuri; Tamera J. Corte; Kerri A. Johannson; Marlies Wijsenbeek; Stephane Jouneau; Andreas Michael; Manuel Quaresma; Klaus B. Rohr; Anne Marie Russell; Susanne Stowasser; Toby M. Maher; the INMARK trial investigators

doi:10.1183/13993003.01518-2020

Home spirometry in patients with idiopathic pulmonary fibrosis: Data from the INMARK trial

Imre Noth, Vincent Cottin, Nazia Chaudhuri, Tamera J. Corte, Kerri A. Johannson, Marlies Wijsenbeek, Stephane Jouneau, Andreas Michael, Manuel Quaresma, Klaus B. Rohr, Anne Marie Russell, Susanne Stowasser, Toby M. Maher^*, the INMARK trial investigators

^*Corresponding author for this work

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

51 Citations (Scopus)

Abstract

Background Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). Methods Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients. Results In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks). Conclusion Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.

Original language	English
Article number	2001518
Journal	European Respiratory Journal
Volume	58
Issue number	1
DOIs	https://doi.org/10.1183/13993003.01518-2020
Publication status	Published - 1 Jul 2021

Bibliographical note

Funding Information:
Support statement: The INMARK trial was funded by Boehringer Ingelheim. Funding information for this article has been deposited with the Crossref Funder Registry.

Acknowledgements: The authors thank the patients who participated in this trial. The authors did not receive payment for development of this manuscript. Writing assistance was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn (London, UK), which was contracted and funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

Publisher Copyright:
© ERS 2021

Access to Document

10.1183/13993003.01518-2020

https://erj.ersjournals.com/content/erj/58/1/2001518.full.pdfLicence: CC BY

Cite this

Noth, I., Cottin, V., Chaudhuri, N., Corte, T. J., Johannson, K. A., Wijsenbeek, M., Jouneau, S., Michael, A., Quaresma, M., Rohr, K. B., Russell, A. M., Stowasser, S., Maher, T. M., & the INMARK trial investigators (2021). Home spirometry in patients with idiopathic pulmonary fibrosis: Data from the INMARK trial. European Respiratory Journal, 58(1), Article 2001518. https://doi.org/10.1183/13993003.01518-2020

@article{6af5a534007f4280a4c88716147a88b1,

title = "Home spirometry in patients with idiopathic pulmonary fibrosis: Data from the INMARK trial",

abstract = "Background Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). Methods Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients. Results In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75\% in every 4-week period. Over 52 weeks, mean adherence was 86\%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks). Conclusion Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.",

author = "Imre Noth and Vincent Cottin and Nazia Chaudhuri and Corte, \{Tamera J.\} and Johannson, \{Kerri A.\} and Marlies Wijsenbeek and Stephane Jouneau and Andreas Michael and Manuel Quaresma and Rohr, \{Klaus B.\} and Russell, \{Anne Marie\} and Susanne Stowasser and Maher, \{Toby M.\} and \{the INMARK trial investigators\}",

note = "Funding Information: Support statement: The INMARK trial was funded by Boehringer Ingelheim. Funding information for this article has been deposited with the Crossref Funder Registry. Acknowledgements: The authors thank the patients who participated in this trial. The authors did not receive payment for development of this manuscript. Writing assistance was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn (London, UK), which was contracted and funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Publisher Copyright: {\textcopyright} ERS 2021",

year = "2021",

month = jul,

day = "1",

doi = "10.1183/13993003.01518-2020",

language = "English",

volume = "58",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "1",

}

Noth, I, Cottin, V, Chaudhuri, N, Corte, TJ, Johannson, KA, Wijsenbeek, M, Jouneau, S, Michael, A, Quaresma, M, Rohr, KB, Russell, AM, Stowasser, S, Maher, TM & the INMARK trial investigators 2021, 'Home spirometry in patients with idiopathic pulmonary fibrosis: Data from the INMARK trial', European Respiratory Journal, vol. 58, no. 1, 2001518. https://doi.org/10.1183/13993003.01518-2020

TY - JOUR

T1 - Home spirometry in patients with idiopathic pulmonary fibrosis

T2 - Data from the INMARK trial

AU - Noth, Imre

AU - Cottin, Vincent

AU - Chaudhuri, Nazia

AU - Corte, Tamera J.

AU - Johannson, Kerri A.

AU - Wijsenbeek, Marlies

AU - Jouneau, Stephane

AU - Michael, Andreas

AU - Quaresma, Manuel

AU - Rohr, Klaus B.

AU - Russell, Anne Marie

AU - Stowasser, Susanne

AU - Maher, Toby M.

AU - the INMARK trial investigators

N1 - Funding Information: Support statement: The INMARK trial was funded by Boehringer Ingelheim. Funding information for this article has been deposited with the Crossref Funder Registry. Acknowledgements: The authors thank the patients who participated in this trial. The authors did not receive payment for development of this manuscript. Writing assistance was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn (London, UK), which was contracted and funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Publisher Copyright: © ERS 2021

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Background Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). Methods Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients. Results In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks). Conclusion Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.

AB - Background Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). Methods Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients. Results In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks). Conclusion Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.

UR - https://www.scopus.com/pages/publications/85108323980

U2 - 10.1183/13993003.01518-2020

DO - 10.1183/13993003.01518-2020

M3 - Article

C2 - 33419890

AN - SCOPUS:85108323980

SN - 0903-1936

VL - 58

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 1

M1 - 2001518

ER -

Home spirometry in patients with idiopathic pulmonary fibrosis: Data from the INMARK trial

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this